RxDoctor Payments Data

Megan Collier

Nurse Practitioner · Rapid City, SDNPI 1851815385

Payments from drug & device makers

$828in general payments, 2019–2025

Across 27 payments — averaging $30.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Madrigal Pharmaceuticals$289
  • Amgen$167
  • AbbVie$54
  • Novo Nordisk$52
  • Lilly USA, LLC$50
  • Novartis$40
  • plus $175 from 8 others

What the payments were for

  • Food & beverage$828100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$828 in reported general payments places this provider in the 75th percentile of 504 nurse practitioner providers in South Dakota.

See all nurse practitioner providers in South Dakota

Medicare billing

Part B allowed, 2024
$247,107
Medicare patients
259
Services billed
8,444

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide71$96,249
OzempicSemaglutide57$83,383
JardianceEmpagliflozin27$38,564
EliquisApixaban15$19,760
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$13,623
JanuviaSitagliptin Phosphate12$13,255
Fluticasone-SalmeterolFluticasone Propion/Salmeterol32$7,783
Breo ElliptaFluticasone/Vilanterol12$7,713
Advair HfaFluticasone Propion/Salmeterol12$5,929
Atorvastatin Calcium449$4,028
Metoprolol Succinate226$3,617
Celecoxib47$3,113
Levothyroxine Sodium394$3,099
SynthroidLevothyroxine Sodium38$3,040
Albuterol Sulfate HfaAlbuterol Sulfate77$2,706

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$50$96,24971 claims
Novo NordiskOzempic$52$83,38357 claims
Boehringer IngelheimJardiance$34$38,56427 claims
AstraZenecaBreztri Aerosphere$18$13,62313 claims
AbbVieSynthroid$54$3,04038 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 504 nurse practitioner providers in South Dakota.

Other nurse practitioner in Rapid City

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →